A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and 1H- and 13C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. © 2013 American Chemical Society.

NOVEL ANALGESIC/ANTI-INFLAMMATORY AGENTS: 1,5-DIARYLPYRROLE NITROOXYALKYL ETHERS AND RELATED COMPOUNDS AS CYCLOOXYGENASE-2 INHIBITING NITRIC OXIDE DONORS

BROGI, SIMONE;CALDERONE, VINCENZO;MARTELLI, ALMA;TESTAI, LARA;
2013

Abstract

A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and 1H- and 13C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. © 2013 American Chemical Society.
M., Anzini; A., DI CAPUA; S., Valenti; Brogi, Simone; M., Rovini; G., Giuliani; A., Cappelli; S., Vomero; L., Chiasserini; A., Sega; G., Poce; G., Giorgi; Calderone, Vincenzo; Martelli, Alma; Testai, Lara; L., Sautebin; A., Rossi; S., Pace; C., Ghelardini; L., DI CESARE MANNELLI; V., Benetti; A., Giordani; P., Anzellotti; M., Dovizio; P., Patrignani; M., Biava
File in questo prodotto:
File Dimensione Formato  
Jmc Anzini et al 2013.pdf

solo utenti autorizzati

Descrizione: Articolo finale
Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 3.56 MB
Formato Adobe PDF
3.56 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/225332
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 41
social impact